LOGIN  |  REGISTER
Chimerix
Recursion

Waystar to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on February 18, 2025

January 28, 2025 | Last Trade: US$37.64 0.25 -0.66

LEHI, Utah and LOUISVILLE, Ky., Jan. 28, 2025 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, announced today that it will report financial results for the fourth quarter and fiscal year ended December 31, 2024, before market open on Tuesday, February 18, 2025. The company will discuss its financial results on a conference call at 8:30 a.m. Eastern Time that same day.

A live audio webcast of the conference call will be available on Waystar's investor relations website at https://investors.waystar.com/news-events/events. The webcast will be archived on the site for those unable to listen in real time.

About Waystar

Waystar's mission-critical software is purpose-built to simplify healthcare payments so providers can prioritize patient care and optimize their financial performance. Waystar serves approximately 30,000 clients, representing over 1 million distinct providers, including 16 of 20 institutions on the U.S. News Best Hospitals Honor Roll. Waystar's enterprise-grade platform annually processes over 5 billion healthcare payment transactions, including over $1.2 trillion in annual gross claims and spanning approximately 50% of U.S. patients. Waystar strives to transform healthcare payments so providers can focus on what matters most: their patients and communities. Discover the way forward at waystar.com.

Media Contact
Kristin Lee
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Contact
Sandy Draper
This email address is being protected from spambots. You need JavaScript enabled to view it.
502-238-9511

Recursion

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page